Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) (RESPONSE)

This study has been completed.
Information provided by:
Genentech, Inc. Identifier:
First received: November 17, 2004
Last updated: July 1, 2015
Last verified: March 2011
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.

Condition Phase
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Enrollment: 1846
Study Start Date: March 2005
Study Completion Date: October 2009

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
managed care organizations, community or physician practices, and academic centers in the United States

Inclusion Criteria:

  • Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis and be a candidate for treatment with Raptiva
  • Are being treated with or initiating Raptiva therapy at the time of enrollment
  • Be able to provide written informed consent
  • Be willing and able to fully to participate for the duration of patient follow-up (5 years)

Exclusion Criterion:

  • Have previously received at least one dose of Raptiva and are not currently using or restarting treatment with Raptiva at the time of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00096928

  Show 182 Study Locations
Sponsors and Collaborators
Genentech, Inc.
Study Director: Ivor Caro, M.D. Genentech, Inc.
  More Information

Responsible Party: Disclosures Group, Genentech, Inc. Identifier: NCT00096928     History of Changes
Other Study ID Numbers: ACD3101g
Study First Received: November 17, 2004
Last Updated: July 1, 2015

Keywords provided by Genentech, Inc.:
Plaque Psoriasis

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases processed this record on May 25, 2017